Merck's Raltegravir HIV drug shows considerable promise in Australian trials.
It is shown to effectively lower the amount of virus in the blood to undetectable levels in 62 percent of people taking it in combination with other anti-HIV medicines.
AIDS / HIV - Treatment
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV
Advertisement
Only one in three people who received a placebo plus other anti-HIV medicines had the amount of virus in the blood reduced to similar levels.
Research co-authored by the University of New South Wales' (UNSW) National Centre in HIV Epidemiology and Clinical Research (NCHECR) shows that the majority of patients who have not responded to traditional treatments have had good results from the new combination therapy.
![New HIV Drug That Halts Progression of HIV Introduced in Britain]( "New HIV Drug That Halts Progression of HIV Introduced in Britain")
Providing a fresh impetus to the fight against AIDS, a new class of medication for people with HIV was introduced in Britain on Monday.
The drug raltegravir is already available in Australia and is listed on the Pharmaceutical Benefits Scheme. Clinical trials show that it is safe, effective and with minimal side-effects when used with other anti-HIV medicines.
"This is the first drug in a new class of antiretroviral drugs called integrase inhibitors," said UNSW Professor David Cooper AO, the Director of NCHECR.
"The drug has a different mechanism of action, is very potent, seems very safe and has helped patients who have a virus that is resistant to older drugs and classes," said Professor Cooper.
Raltegravir effectively decreases HIV viral loads after 24 weeks of use among HIV-positive people who have not responded to other treatments, according to a study published last year in Lancet.
Raltegravir works by blocking an HIV enzyme called integrase. Integrase is one of the three enzymes necessary for HIV to replicate in the body, and integrase inhibitors stop HIV from inserting its genes into uninfected DNA. The other two enzymes necessary for viral replication, reverse transcriptase and protease, already are targeted by a variety of antiretrovirals.
"It initially will be used in developed countries, but hopefully, it will be made available at cheaper prices for patients in developing countries who are facing the same problems," said Professor Cooper.
The results were based on analyses of viral load reductions and CD4 cell count increases. A high CD4 cell count is crucial for a healthy immune system.
Professor Cooper said the efficacy shown at 48 weeks of treatment was consistent with observations at 24 weeks, indicating that the drug in combination has a durable effect.
The study shows the drug is well-tolerated by patients. It showed that only 0.9 percent of those receiving raltegravir discontinued therapy due to side-effects including nausea and headaches.
The overall results have been drawn from two major ongoing clinical trials in Europe, Asia, Australia and North and South America. Both studies are supported by Merck & Co, Inc., the manufacturer of raltegravir.
Professor Cooper is the first author of the second of two papers published in this edition of the New England Journal of Medicine. The first is led by Professor Roy Steigbigel from Stony Brook University Medical Center.
Source: Medindia
GPL/S
New HIV Drug That Halts Progression of HIV Introduced in Britain
Providing a fresh impetus to the fight against AIDS, a new class of medication for people with HIV was introduced in Britain on Monday.
Advertisement
The drug raltegravir is already available in Australia and is listed on the Pharmaceutical Benefits Scheme. Clinical trials show that it is safe, effective and with minimal side-effects when used with other anti-HIV medicines.
"This is the first drug in a new class of antiretroviral drugs called integrase inhibitors," said UNSW Professor David Cooper AO, the Director of NCHECR.
"The drug has a different mechanism of action, is very potent, seems very safe and has helped patients who have a virus that is resistant to older drugs and classes," said Professor Cooper.
Raltegravir effectively decreases HIV viral loads after 24 weeks of use among HIV-positive people who have not responded to other treatments, according to a study published last year in Lancet.
Raltegravir works by blocking an HIV enzyme called integrase. Integrase is one of the three enzymes necessary for HIV to replicate in the body, and integrase inhibitors stop HIV from inserting its genes into uninfected DNA. The other two enzymes necessary for viral replication, reverse transcriptase and protease, already are targeted by a variety of antiretrovirals.
"It initially will be used in developed countries, but hopefully, it will be made available at cheaper prices for patients in developing countries who are facing the same problems," said Professor Cooper.
The results were based on analyses of viral load reductions and CD4 cell count increases. A high CD4 cell count is crucial for a healthy immune system.
Professor Cooper said the efficacy shown at 48 weeks of treatment was consistent with observations at 24 weeks, indicating that the drug in combination has a durable effect.
The study shows the drug is well-tolerated by patients. It showed that only 0.9 percent of those receiving raltegravir discontinued therapy due to side-effects including nausea and headaches.
The overall results have been drawn from two major ongoing clinical trials in Europe, Asia, Australia and North and South America. Both studies are supported by Merck & Co, Inc., the manufacturer of raltegravir.
Professor Cooper is the first author of the second of two papers published in this edition of the New England Journal of Medicine. The first is led by Professor Roy Steigbigel from Stony Brook University Medical Center.
Source: Medindia
GPL/S
Expected Approval by FDA on Merck's Raltegravir Could Be a Milestone in AIDS/HIV Fight, Wall Street Journal Reports
FDA's expected approval this week of Merck's antiretroviral drug raltegravir could "break new ground" in the fight against HIV/AIDS, the Wall Street Journal reports.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest AIDS/HIV News
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
